The Gene &Virus Therapy Program (GVTP) currently comprises twelve members, both basic scientists and clinician investigators from eight departments and divisions working interactively to develop novel, genetically based approaches to the treatment of cancer. The goals of the program are: (1) to enhance understanding of the biology of the viruses and cells that are used to create new gene delivery systems;(2) to advance the technology base from which new gene and virus based therapies can be created;and (3) to improve the outcomes of cancer treatment by developing new gene and virus based therapies and testing them in the clinic. The major research themes are (I) preclinical and clinical pharmacology;(II) vector targeting;(III) cellular carriers;and (IV) imrhunomodulation. Intra-programmatic interactions are intensive, comprising multiple collaborations, regular operational faculty meetings, and scientific exchanges in the context of regular journal clubs and programmatic seminars. Substantive inter-programmatic interactions, essential for the process of clinical translation, have been established between the Gene &Virus Therapy Program, the Immunology &Immunotherapy Program, the Hematologic Malignancies Program, the Women's Cancer Program, the Gastrointestinal Cancer Program, and the Neuro-oncology Program. The Gene &Virus Therapy Program benefits from the strong leadership of Stephen Russell, MD, PhD, a hematologist with considerable stature in the field of gene and virus therapy. The NIH funding base for this program currently stands at $3.5 million per annum in total costs of which 58% is from the National Cancer Institute. Productivity of the program during the current funding period has been substantial, amounting to a total of 320 publications and four Phase I clinical trials in which recombinant viruses that were designed, built, preclinically tested, and manufactured at Mayo Clinic Rochester are being administered to patients with various types of cancer. Additionally, there are several very promising projects in the translational pipeline, including a major inter-programmatic collaboration between the GVTP in Rochester and members of the Gastrointestinal Cancer Program in Mayo Clinic Arizona to advance a recombinant oncolytic vesicular stomatitis virus to clinical testing in patients with hepatocellular carcinoma. 320 total publications;17% intra-programmatic;23% inter-programmatic

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465655
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$259,963
Indirect Cost
$79,996
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications